apatinib

ApprovedSmall molecule

LLaNova Medicines Zhejiang Co., Ltd.

apatinib is one of 937 small molecule programs targeting Glioma. It is currently in Approved.

Indications

259

Total Trials

Active Trials

936

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

AscitesActive, not recruiting

MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Gallbladder CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Oral Squamous Cell CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

GliomaPreclinical

Active, not recruiting

Pancreatic CarcinomaPhase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

AscitesPhase 2

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 1

Active, not recruiting

Gallbladder CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Oral Squamous Cell CarcinomaPhase 1

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Showing 10 of 42 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Approved

17 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Prolia

Amgen

Preclinical

14 5

DATROWAY

Daiichi Sankyo

Preclinical

4 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Voltaren

Novartis

Preclinical

1 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Acupan

YYonsei University

Preclinical

1 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Chemoradiotherapy

NCT06464614

Phase 2Recruiting

Esophageal Squamous Cell Carcinoma

NCT06339619

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT05594095

Phase 2Active, not recruiting

Esophageal Squamous Cell Carcinoma

NCT06281886

Phase 2Not yet recruiting

First-Line Treatment

NCT06694324

Phase 3Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06351020

Clinical

Trials by Indication[1]

Gastric Cancer24 trials

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06385873·32 enrolled

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04267549·47 enrolled

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07464756·80 enrolled

Show 21 more trials

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02485015·80 enrolled

Apatinib for the Elderly Advanced Gastric Cancer

Completed·—·Phase 2·NCT03104283·48 enrolled

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Recruiting·FFujian Cancer Hospital·Phase 2/3·NCT05699655·130 enrolled

Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Unknown status·HHebei Medical University·Phase 2/3·NCT02509806·48 enrolled

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Unknown status·FFudan University·Phase 3·NCT03889626·242 enrolled

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT02697838·20 enrolled

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT01512745·267 enrolled

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·N/A·NCT02764268·60 enrolled

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Not yet recruiting·—·Phase 2·NCT06881017·140 enrolled

Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells

Unknown status·HHebei Medical University·Phase 2/3·NCT02510469·48 enrolled

Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

Unknown status·—·Phase 2·NCT03334591·60 enrolled

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

Unknown status·—·Phase 2·NCT02596256·80 enrolled

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03026881·24 enrolled

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Unknown status·—·Phase 2·NCT03007446·20 enrolled

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT05029453·60 enrolled

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

Unknown status·—·Phase 2·NCT02525237·30 enrolled

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 3·NCT02537171·40 enrolled

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03472365·67 enrolled

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Unknown status·HHebei Medical University·Phase 2·NCT03718624·36 enrolled

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Terminated·WWuhan University·N/A·NCT03349827·20 enrolled

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Active, not recruiting·RRuijin Hospital·Phase 2·NCT06693128·80 enrolled

Breast Cancer13 trials

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Completed·PPeking University Cancer Hospital & Institute·Phase 2·NCT02878057·30 enrolled

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Recruiting·—·Phase 2·NCT06418594·30 enrolled

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05759572·145 enrolled

Show 10 more trials

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02768415·40 enrolled

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03075462·98 enrolled

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer

Active, not recruiting·RRenJi Hospital·Phase 2·NCT03982485·196 enrolled

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07371910·200 enrolled

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Recruiting·WWest China Hospital·Phase 2·NCT05447702·35 enrolled

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Completed·FFudan University·Phase 2·NCT01653561·20 enrolled

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Unknown status·HHebei Medical University Fourth Hospital·Phase 2/3·NCT03580395·200 enrolled

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer

Completed·GGuangdong Provincial People's Hospital·Phase 2·NCT03243838·31 enrolled

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Unknown status·YYan Li·Phase 2·NCT03457467·30 enrolled

Non-Small Cell Lung Cancer11 trials

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07031154·43 enrolled

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Unknown status·TThird Military Medical University·Phase 2·NCT02733107·25 enrolled

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

Unknown status·WWuhan University·Phase 2·NCT04878107·88 enrolled

Show 8 more trials

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT02780778·20 enrolled

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03777124·25 enrolled

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT04506242·74 enrolled

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01270386·136 enrolled

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02332512·417 enrolled

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Withdrawn·XXinqiao Hospital of Chongqing·Phase 2·NCT03190239

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Unknown status·—·Phase 2·NCT03416231·20 enrolled

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Withdrawn·XXinqiao Hospital of Chongqing·Phase 4·NCT03792503

Hepatocellular Carcinoma10 trials

The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

Unknown status·GGuangxi Medical University·Phase 2·NCT03511703·40 enrolled

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT03722875·45 enrolled

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06538935·80 enrolled

Show 7 more trials

The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus

Unknown status·GGuangxi Medical University·Phase 2·NCT03520257·50 enrolled

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·N/A·NCT06893887·300 enrolled

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT03510416·22 enrolled

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT04014101·40 enrolled

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03046979·30 enrolled

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03398122·248 enrolled

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 1/2·NCT02942329·60 enrolled

Ovarian Cancer7 trials

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

Unknown status·TThe People's Hospital of Leshan·Phase 2·NCT03393507·34 enrolled

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04000295·280 enrolled

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Unknown status·YYang Zhijun·Phase 2·NCT03298074·60 enrolled

Show 4 more trials

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04068974·28 enrolled

Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

Unknown status·—·Phase 2·NCT03547375·69 enrolled

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Terminated·FFirst Affiliated Hospital of Harbin Medical University·Phase 2·NCT03587129·1 enrolled

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03262545·60 enrolled

73 more indications

Colorectal Cancer6 trials

Apatinib for Resectable Colorectal Cancer

Withdrawn·—·N/A·NCT03228043

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Completed·HHuashan Hospital·Phase 3·NCT03365765·63 enrolled

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01531777·40 enrolled

Show 3 more trials

Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients

Unknown status·HHui ting Xu，MD·Phase 2·NCT03210064·42 enrolled

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04067986·62 enrolled

Apatinib in Refractory Colorectal Cancer

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03190616·54 enrolled

Triple-Negative Breast Cancer6 trials

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03348098·20 enrolled

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Completed·FFudan University·Phase 2·NCT01176669·60 enrolled

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Completed·FFudan University·Phase 2·NCT03254654·66 enrolled

Show 3 more trials

This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03650738·60 enrolled

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT03775928·80 enrolled

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03735082·29 enrolled

Thyroid Cancer5 trials

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT03048877·118 enrolled

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

Unknown status·—·Phase 2·NCT03300765·20 enrolled

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Completed·PPeking Union Medical College Hospital·Phase 2·NCT02731352·20 enrolled

Show 2 more trials

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting·WWest China Hospital·Phase 2·NCT06482086·75 enrolled

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03199677·40 enrolled

Camrelizumab5 trials

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Unknown status·HHuiqiang Huang·Phase 1/2·NCT04476459·33 enrolled

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04303741·46 enrolled

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Unknown status·ZZhongda Hospital·N/A·NCT04559607·188 enrolled

Show 2 more trials

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

Completed·PPeking Union Medical College Hospital·Phase 2·NCT04047017·20 enrolled

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05198609·214 enrolled

Nasopharyngeal Carcinoma5 trials

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT03213587·51 enrolled

ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

Terminated·SSun Yat-sen University·Phase 2·NCT02874651·25 enrolled

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Completed·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03180476·21 enrolled

Show 2 more trials

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04548271·25 enrolled

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04547088·27 enrolled

Cervical Cancer4 trials

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04974944·172 enrolled

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Completed·SSun Yat-sen University·Phase 2·NCT03816553·45 enrolled

Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.

Unknown status·—·Phase 2·NCT03546855·69 enrolled

Show 1 more trial

Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer

Unknown status·TThird Military Medical University·N/A·NCT03029013·30 enrolled

Glioma4 trials

Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas

Unknown status·WWuHui·Phase 2·NCT04253873·40 enrolled

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Unknown status·TThe First Affiliated Hospital of Zhengzhou University··NCT04216550·600 enrolled

TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT

Unknown status·TThe Second Hospital of Hebei Medical University·Phase 2·NCT03741244·211 enrolled

Show 1 more trial

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Unknown status·WWest China Hospital·Phase 2·NCT03390062·30 enrolled

Esophageal Squamous Cell Carcinoma4 trials

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Completed·PPeking University·Phase 1·NCT02645864·12 enrolled

Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Terminated·PPeking University·Phase 2·NCT03251417·11 enrolled

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT06281886·170 enrolled

Show 1 more trial

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06339619·32 enrolled

Esophageal Cancer4 trials

A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib

Withdrawn·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT03787251

Apatinib for Metastatic Esophageal Cancer.

Unknown status·HHangzhou Cancer Hospital·Phase 2·NCT02544737·29 enrolled

Study of Apatinib in Metastatic Esophageal Cancer

Unknown status·HHuai'an First People's Hospital·Phase 2·NCT02683655·40 enrolled

Show 1 more trial

An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT03285906·30 enrolled

Pancreatic Cancer4 trials

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

Unknown status·—·Phase 2·NCT03662035·30 enrolled

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

Unknown status·FFudan University·Phase 2·NCT04101929·126 enrolled

Apatinib as Second-line Treatment of Advanced Pancreatic Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 2·NCT02726854·30 enrolled

Show 1 more trial

A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT02863367·30 enrolled

First-line Treatment4 trials

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Recruiting·SSun Yat-sen University·Phase 3·NCT05854849·244 enrolled

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Unknown status·WWest China Hospital·Phase 1/2·NCT03201146·48 enrolled

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03164694

Show 1 more trial

First-line Treatment of Advanced/unresectable DDLPS

Not yet recruiting·FFudan University·Phase 2·NCT06694324·49 enrolled

Intrahepatic Cholangiocarcinoma3 trials

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Completed·PPeking Union Medical College Hospital·Phase 2·NCT03251443·34 enrolled

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03521219·30 enrolled

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Recruiting·LLei ZHAO·Phase 2·NCT06296563·20 enrolled

Small Cell Lung Cancer3 trials

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Completed·—·Phase 2·NCT02945852·40 enrolled

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06786312·34 enrolled

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

Unknown status·—·Phase 3·NCT03651219·90 enrolled

Lung Adenocarcinoma3 trials

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04459078·63 enrolled

Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03376737·120 enrolled

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Unknown status·FFirst Affiliated Hospital of Kunming Medical University·Phase 2·NCT02704767·60 enrolled

Osteosarcoma3 trials

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

Completed·PPeking University People's Hospital·Phase 2·NCT03359018·43 enrolled

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

Unknown status·RRuijin Hospital·Phase 2·NCT03742193·43 enrolled

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

Suspended·PPeking University People's Hospital·Phase 2·NCT04824352·44 enrolled

Apatinib3 trials

A Study To Test The Effect Of Apatinib On P450 Enzymes

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03245307·20 enrolled

A Phase II Study of Apatinib in STS Patients

Unknown status·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 2·NCT03064243·53 enrolled

Study of the Combination of Apatinib and POF

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03707639·26 enrolled

Unresectable2 trials

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

Unknown status·YYanqiao Zhang·Phase 2·NCT03793725·30 enrolled

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05853172·30 enrolled

Head and Neck Cancer2 trials

Apatinib for Advanced Non-squamous Head and Neck Cancer

Unknown status·—·Phase 2·NCT02989259·30 enrolled

The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer

Unknown status·—·Phase 2·NCT02943252·30 enrolled

Lung Cancer2 trials

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

Unknown status·JJunling Li·Phase 2·NCT03129698·52 enrolled

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Unknown status·SSun Yat-sen University·Phase 3·NCT02824458·246 enrolled

Metastatic Colorectal Cancer2 trials

Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer

Unknown status·LLiqiang Zhong·Phase 2·NCT03412994·60 enrolled

Apatinib in the Treatment of Metastatic Colorectal Cancer

Unknown status·FFudan University·Phase 2·NCT03403452·33 enrolled

Gastric Adenocarcinoma2 trials

Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03788174·26 enrolled

XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

Unknown status·—·Phase 1/2·NCT03599778·52 enrolled

Adenocarcinoma2 trials

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Withdrawn·PPeking University·Phase 2·NCT04863430

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Unknown status·SSir Run Run Shaw Hospital·Phase 1·NCT03071042·12 enrolled

Carcinoma2 trials

Apatinib for Advanced Biliary Carcinoma

Unknown status·FFudan University·Phase 2·NCT03427242·55 enrolled

Apatinib for Advanced Lung Squmamous Carcinoma

Unknown status·—·Phase 4·NCT03725423·50 enrolled

Non-squamous NSCLC2 trials

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

Unknown status·HHebei Medical University Fourth Hospital·N/A·NCT03634059·80 enrolled

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Unknown status·JJunling Li·Phase 2·NCT04670913·30 enrolled

Melanoma2 trials

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03383237·20 enrolled

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT03422445·30 enrolled

Adjuvant Therapy2 trials

Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT03261791·30 enrolled

A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03609489·40 enrolled

Second-line Treatment2 trials

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Unknown status·—·Phase 2·NCT03116555·37 enrolled

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Unknown status·FFeng Wang·Phase 3·NCT05049681·234 enrolled

Chemotherapy2 trials

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Unknown status·TThe First Hospital of Jilin University·Phase 2·NCT03758677·30 enrolled

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03671265·20 enrolled

Recurrent or Refractory1 trial

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Completed·RRongjie Tao·Phase 2·NCT03660761·25 enrolled

Esophageal Squamous Cell Cancer1 trial

Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Unknown status·TThe First Affiliated Hospital of Anhui Medical University·Phase 2·NCT03224221·189 enrolled

Head and Neck1 trial

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

Unknown status·CChina International Medical Foundation·Phase 1/2·NCT03654612·30 enrolled

Brain Injury1 trial

Effect and Safety of Apatinib on Radiation-Induced Brain Injury

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04152681·36 enrolled

Adrenal Cortical Carcinoma1 trial

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Recruiting·WWest China Hospital·Phase 2·NCT06831175·28 enrolled

Patients With Advanced Solid Tumors1 trial

Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

Unknown status·TThe First People's Hospital of Lianyungang·Phase 1/2·NCT02844881·60 enrolled

Adenoid Cystic Carcinoma1 trial

Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma

Unknown status·SShanghai Proton and Heavy Ion Center·Phase 2·NCT02942693·50 enrolled

First Line Therapy1 trial

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03764293·543 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 3·NCT06351020·387 enrolled

Advanced Solid Tumors1 trial

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04569916·30 enrolled

Liver Cancer1 trial

Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

Unknown status·ZZhejiang Cancer Hospital·Phase 2/3·NCT02702323·40 enrolled

Neuroendocrine Carcinoma1 trial

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Unknown status·HHuazhong University of Science and Technology·Phase 2·NCT05142865·30 enrolled

Advanced Malignancies1 trial

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

Terminated·UUniversity of Utah·Phase 1·NCT03407976·5 enrolled

Immunotherapy1 trial

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

Recruiting·GGrandPharma (China) Co., Ltd.·Phase 2·NCT07334483·120 enrolled

Esophagus Cancer1 trial

Apatinib Treatment for Advanced Esophagus Cancer

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03170310·60 enrolled

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03163381·40 enrolled

Tumor1 trial

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Recruiting·LLaNova Medicines Zhejiang Co., Ltd.·Phase 2·NCT05934331·276 enrolled

Anti-PD-1 Antibody1 trial

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT03394287·40 enrolled

Lymphoma1 trial

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Unknown status·ZZhengzhou University·Phase 4·NCT03631862·100 enrolled

Treatment1 trial

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03389256·144 enrolled

Malignancies1 trial

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT06181032·35 enrolled

Cholangiocarcinoma1 trial

Advanced or Metastatic Cholangiocarcinoma

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT05653817·60 enrolled

ALK-positive Advanced NSCLC1 trial

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT04425135·59 enrolled

Adverse Events1 trial

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Completed·SShandong Cancer Hospital and Institute·Phase 4·NCT03384511·38 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

Unknown status·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT03709953·33 enrolled

Microwave Ablation1 trial

A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Not yet recruiting·—·Phase 2·NCT06537505·60 enrolled

Radiotherapy1 trial

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

Unknown status·UUnknown Sponsor·Phase 2·NCT03801200·90 enrolled

Advanced NSCLC1 trial

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

Unknown status·—·Phase 2·NCT03411967·20 enrolled

Metastasis1 trial

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Withdrawn·SSun Yat-sen University·Phase 2·NCT04682249

Unresectable Biliary Tract Carcinoma1 trial

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06749730·63 enrolled

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

Conversion Therapy1 trial

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

Recruiting·—·Phase 2·NCT07353684·49 enrolled

Angiogenesis1 trial

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Unknown status·FFudan University·Phase 1·NCT00633490·18 enrolled

Digestive System Cancer1 trial

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06099821·39 enrolled

Advanced1 trial

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07157969·300 enrolled

Adverse Drug Reactions1 trial

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Unknown status·SSun Yat-sen University·Phase 4·NCT03475589·217 enrolled

Gallbladder Carcinoma1 trial

Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma

Unknown status·—·Phase 2·NCT03702491·138 enrolled

Pancreatic Carcinoma1 trial

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04415385·48 enrolled

Locally Advanced1 trial

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT03355612·456 enrolled

Biliary Tract Cancer1 trial

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Completed·—·Phase 2·NCT04720131·28 enrolled

Ascites1 trial

A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites

Unknown status·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT03020979·120 enrolled

Glioblastoma1 trial

Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma

Unknown status·FFuzhou General Hospital··NCT03567135·60 enrolled

Metastatic Prostate Cancer1 trial

Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer

Completed·SSichuan Provincial People's Hospital·N/A·NCT02998242·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 259 trial records for apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LaNova Medicines Zhejiang Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: LLaNova Medicines Zhejiang Co., Ltd.

apatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Gastric Cancer24 trials

Breast Cancer13 trials

Non-Small Cell Lung Cancer11 trials

Hepatocellular Carcinoma10 trials

Ovarian Cancer7 trials

Colorectal Cancer6 trials

Triple-Negative Breast Cancer6 trials

Thyroid Cancer5 trials

Camrelizumab5 trials

Nasopharyngeal Carcinoma5 trials

Cervical Cancer4 trials

Glioma4 trials

Esophageal Squamous Cell Carcinoma4 trials

Esophageal Cancer4 trials

Pancreatic Cancer4 trials

First-line Treatment4 trials

Intrahepatic Cholangiocarcinoma3 trials

Small Cell Lung Cancer3 trials

Lung Adenocarcinoma3 trials

Osteosarcoma3 trials

Apatinib3 trials

Unresectable2 trials

Head and Neck Cancer2 trials

Lung Cancer2 trials

Metastatic Colorectal Cancer2 trials

Gastric Adenocarcinoma2 trials

Adenocarcinoma2 trials

Carcinoma2 trials

Non-squamous NSCLC2 trials

Melanoma2 trials

Adjuvant Therapy2 trials

Second-line Treatment2 trials

Chemotherapy2 trials

Recurrent or Refractory1 trial

Esophageal Squamous Cell Cancer1 trial

Head and Neck1 trial

Brain Injury1 trial

Adrenal Cortical Carcinoma1 trial

Patients With Advanced Solid Tumors1 trial

Adenoid Cystic Carcinoma1 trial

First Line Therapy1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Advanced Solid Tumors1 trial

Liver Cancer1 trial

Neuroendocrine Carcinoma1 trial

Advanced Malignancies1 trial

Immunotherapy1 trial

Esophagus Cancer1 trial

Chemoradiotherapy1 trial

Renal Cell Carcinoma1 trial

Soft Tissue Sarcoma1 trial

Tumor1 trial

Anti-PD-1 Antibody1 trial

Lymphoma1 trial

Treatment1 trial

Malignancies1 trial

Cholangiocarcinoma1 trial

ALK-positive Advanced NSCLC1 trial

Adverse Events1 trial

Efficacy and Safety1 trial

Microwave Ablation1 trial

Radiotherapy1 trial

Advanced NSCLC1 trial

Metastasis1 trial

Unresectable Biliary Tract Carcinoma1 trial

PTCL1 trial

Conversion Therapy1 trial

Angiogenesis1 trial

Digestive System Cancer1 trial

Advanced1 trial

Adverse Drug Reactions1 trial

Gallbladder Carcinoma1 trial

Pancreatic Carcinoma1 trial